JP2004529132A - １，２，３，４−テトラヒドロイソキノリン誘導体 - Google Patents

１，２，３，４−テトラヒドロイソキノリン誘導体 Download PDF

Info

Publication number
JP2004529132A
JP2004529132A JP2002576237A JP2002576237A JP2004529132A JP 2004529132 A JP2004529132 A JP 2004529132A JP 2002576237 A JP2002576237 A JP 2002576237A JP 2002576237 A JP2002576237 A JP 2002576237A JP 2004529132 A JP2004529132 A JP 2004529132A
Authority
JP
Japan
Prior art keywords
dimethoxy
ethyl
dihydro
urea
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002576237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529132A5 (https=
Inventor
アイサオウイ ハメッド
ビンカート クリストフ
マーチン　クローゼル
マチス ボリス
ミューラー クラウス
ナイラー オリバー
シェルツ ミッシェル
ヴェルカー ジョルグ
トーマス　ウィーラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2004529132A publication Critical patent/JP2004529132A/ja
Publication of JP2004529132A5 publication Critical patent/JP2004529132A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
JP2002576237A 2001-03-27 2002-03-20 １，２，３，４−テトラヒドロイソキノリン誘導体 Abandoned JP2004529132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0103422 2001-03-27
EP0109845 2001-08-27
PCT/EP2002/003131 WO2002076979A1 (en) 2001-03-27 2002-03-20 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists

Publications (2)

Publication Number Publication Date
JP2004529132A true JP2004529132A (ja) 2004-09-24
JP2004529132A5 JP2004529132A5 (https=) 2006-01-05

Family

ID=29421788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576237A Abandoned JP2004529132A (ja) 2001-03-27 2002-03-20 １，２，３，４−テトラヒドロイソキノリン誘導体

Country Status (16)

Country Link
US (2) US6815451B2 (https=)
EP (1) EP1379523B1 (https=)
JP (1) JP2004529132A (https=)
KR (1) KR20040016844A (https=)
CN (1) CN1288148C (https=)
AT (1) ATE300533T1 (https=)
BR (1) BR0207715A (https=)
CA (1) CA2441790A1 (https=)
DE (1) DE60205234T2 (https=)
ES (1) ES2246399T3 (https=)
HU (1) HUP0402508A2 (https=)
IL (1) IL157093A0 (https=)
MX (1) MXPA03008639A (https=)
NO (1) NO20034230D0 (https=)
NZ (1) NZ527276A (https=)
WO (1) WO2002076979A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526770A (ja) * 2002-03-13 2005-09-08 ザ ユニバーシティ オブ テネシー リサーチ ファウンデイション 置換テトラヒドロイソキノリン化合物、調製方法、およびその使用
WO2006126255A1 (ja) * 2005-05-24 2006-11-30 Daito Chemix Corporation Ｎ－（２－ブロモエチル）カルバミン酸ｔｅｒｔ－ブチルの製造方法
WO2008123582A1 (ja) * 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
JP2009544623A (ja) * 2006-07-20 2009-12-17 スミスクライン・ビーチャム・コーポレイション モルホリニルおよびピロリジニル類似体
JP2012522060A (ja) * 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
JP2013060473A (ja) * 2006-01-10 2013-04-04 Janssen Pharmaceutica Nv ウロテンシンｉｉ受容体拮抗薬
JP2023532312A (ja) * 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
JP2006505533A (ja) * 2002-09-17 2006-02-16 アクテリオン　ファマシューティカルズ　リミテッド １−ピリジン−４−イル−尿素誘導体
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
WO2004099179A1 (en) * 2003-05-07 2004-11-18 Actelion Pharmaceuticals Ltd Piperazine-alkyl-ureido derivatives
CA2523568A1 (en) * 2003-05-08 2004-11-18 Actelion Pharmaceuticals Ltd Novel piperidine derivatives
US7750161B2 (en) * 2003-09-26 2010-07-06 Daniel Bur Pyridine derivatives
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
MX2007004293A (es) 2004-10-12 2007-06-18 Actelion Pharmaceuticals Ltd 1[2-(4-bencil-4-hidroxi-piperidin-1-il)-etil]-3-(2-metil-quinolin -4-il)-urea como la sal de sulfato cristalina.
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
MX2010010773A (es) * 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
US9238657B2 (en) 2008-10-31 2016-01-19 Shionogi & Co., Ltd. Cephalosporin having catechol group
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US20100312480A1 (en) * 2009-04-24 2010-12-09 Hansteen Fredrik Method for monitoring fluid flow in a multi-layered system
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
RU2020126188A (ru) * 2018-01-10 2022-02-10 Альинки Байофарма Соединения тетрагидроизохинолина
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途
CN115677579B (zh) * 2022-11-02 2024-05-24 上海药坦药物研究开发有限公司 四氢罂粟碱及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
CA2061260A1 (en) * 1991-02-27 1992-08-28 Kiyofumi Ishikawa Isoquinoline derivatives
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
ATE321751T1 (de) 1999-07-28 2006-04-15 Kirin Brewery Harnstoffderivate als ccr-3 rezeptor-inhibitoren
ES2207566T3 (es) * 1999-12-21 2004-06-01 Smithkline Beecham Corporation Derivados carboxamida de pirrolidina y piperidina como antagonistas del receptor de urotensina-ii.
JP2003518059A (ja) * 1999-12-21 2003-06-03 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
WO2001045694A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
EP1295867A4 (en) 2000-06-28 2005-03-30 Takeda Pharmaceutical BIPHENYL COMPOUND
CA2414976A1 (en) 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Gpr14 antagonistic agent

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526770A (ja) * 2002-03-13 2005-09-08 ザ ユニバーシティ オブ テネシー リサーチ ファウンデイション 置換テトラヒドロイソキノリン化合物、調製方法、およびその使用
WO2006126255A1 (ja) * 2005-05-24 2006-11-30 Daito Chemix Corporation Ｎ－（２－ブロモエチル）カルバミン酸ｔｅｒｔ－ブチルの製造方法
US7432391B2 (en) 2005-05-24 2008-10-07 Daito Chemix Corporation Process for the production of tert-butyl N-(2-bromoethyl)carbamate
JP2013060473A (ja) * 2006-01-10 2013-04-04 Janssen Pharmaceutica Nv ウロテンシンｉｉ受容体拮抗薬
JP2009544623A (ja) * 2006-07-20 2009-12-17 スミスクライン・ビーチャム・コーポレイション モルホリニルおよびピロリジニル類似体
WO2008123582A1 (ja) * 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
US8273766B2 (en) 2007-04-04 2012-09-25 Kowa Company, Ltd. Tetrahydroisoquinoline compound
JP5313881B2 (ja) * 2007-04-04 2013-10-09 興和株式会社 テトラヒドロイソキノリン化合物
JP2012522060A (ja) * 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
JP2023532312A (ja) * 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
JP7828905B2 (ja) 2020-06-30 2026-03-12 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用

Also Published As

Publication number Publication date
NO20034230L (no) 2003-09-23
US20040110744A1 (en) 2004-06-10
CN1494542A (zh) 2004-05-05
KR20040016844A (ko) 2004-02-25
CN1288148C (zh) 2006-12-06
DE60205234D1 (de) 2005-09-01
WO2002076979A1 (en) 2002-10-03
ES2246399T3 (es) 2006-02-16
DE60205234T2 (de) 2006-05-24
CA2441790A1 (en) 2002-10-03
MXPA03008639A (es) 2005-03-07
EP1379523A1 (en) 2004-01-14
BR0207715A (pt) 2004-03-23
NZ527276A (en) 2004-11-26
ATE300533T1 (de) 2005-08-15
EP1379523B1 (en) 2005-07-27
IL157093A0 (en) 2004-02-08
US20040242564A1 (en) 2004-12-02
US6815451B2 (en) 2004-11-09
WO2002076979A8 (en) 2003-11-06
HUP0402508A2 (hu) 2005-03-29
NO20034230D0 (no) 2003-09-23

Similar Documents

Publication Publication Date Title
US6815451B2 (en) 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
KR100848747B1 (ko) 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
US6642228B1 (en) α1b-adrenergic receptor antagonists
US20060094716A1 (en) 1-Pyridin-4-yl-urea derivatives
KR20050114242A (ko) 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
EP1499607A1 (en) 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
JP2001518895A (ja) ソマトスタチン作働薬
WO2006067224A2 (en) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
JP4851328B2 (ja) 新規なピリジン誘導体
JP2007506692A6 (ja) 新規なピリジン誘導体
US20120258957A1 (en) Heterocyclic derivatives
US20060211707A1 (en) Piperazine-alkyl-ureido derivatives
AU2002302449A1 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
ZA200306610B (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists.
US20070010516A1 (en) Novel piperidine derivatives
EP1641776A1 (en) Novel piperidine derivatives
JP2006052181A (ja) 新規なキノリン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050502

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20061226